Step-up and step-down treatment for newly diagnosed arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This Phase 3 study tests whether children with early juvenile idiopathic arthritis do better by starting with one treatment approach and adjusting (stepping up or stepping down) based on how their arthritis responds. It may help find the safest, most effective long-term plan for controlling symptoms with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 2 to 17 years old and has newly diagnosed juvenile idiopathic arthritis (JIA).
- Your child has active arthritis started within the last 6 months.
- Your child has not started any disease-targeting arthritis medicines (no synthetic or biologic DMARDs) yet.
- They fit one of these JIA types: limited/oligoarthritis or rheumatoid-factor negative polyarthritis.
- They can follow study visits and procedures, and you (and your child if appropriate) can sign consent/assent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if removing certain foods can improve arthritis symptoms in children aged 6 to 17. It may be an option if current medicines are not working well or if you want to explore dietary changes.
This study looks at how juvenile idiopathic arthritis (JIA), a type of childhood arthritis, affects joints like the hands, hips, and knees after a person moves from pediatric to adult care. It helps understand if joint damage worsens over time, which could guide future treatment.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study looks at when it may be safe to stop or reduce arthritis medications in children whose juvenile idiopathic arthritis has been inactive for at least 6 months. The goal is to find the best time to stop treatment to avoid side effects while preventing flare-ups.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
Hear when a new Oligoarthritis, Juvenile trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.